Retinal degenerations are the major cause of incurable blindness characterized by loss of retinal photoreceptor cells. Several genes causing these genetic diseases have been identified, however the molecular characterization of a high percentage of patients affected by retinitis pigmentosa (RP), a common form of retinal degeneration, is still unknown. The high genetic heterogeneity of these diseases hampers the comprehension of the pathogenetic mechanism causing photoreceptor cell death. Therapies are not available yet and for this reason there is a lot of interest in understanding the etiology and the pathogenesis of these disorders at a cellular and molecular level. Some common features have been identified in different forms of RP. Apoptosis was reported to be the final outcome in all RP animal models and patients analyzed so far. We recently identified two apoptotic pathways coactivated in photoreceptors undergoing cell death in the retinal degeneration (rd1) mouse model of autosomal recessive RP. Our studies opened new perspectives together with many questions that require deeper analyses in order to take advantage of this knowledge and develop new therapeutic approaches. We believe that minimizing cell demise may represent a promising curing strategy that needs to be exploited for retinal degeneration.
|Data di pubblicazione:||2007|
|Titolo:||Programmed cell death in retinal degeneration - Targeting apoptosis in photoreceptors as potential therapy for retinal degeneration|
|Codice identificativo ISI:||WOS:000245496500005|
|Codice identificativo Scopus:||2-s2.0-34047207833|
|Codice identificativo Pubmed:||17374995|
|Citazione:||Programmed cell death in retinal degeneration - Targeting apoptosis in photoreceptors as potential therapy for retinal degeneration / Marigo, Valeria. - In: CELL CYCLE. - ISSN 1538-4101. - STAMPA. - 6(2007), pp. 652-655.|
|Tipologia||Articolo su rivista|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris